SUSTANON 250 INJECTION [SIN04555P]
Active ingredients: TESTOSTERONE DECANOATE | TESTOSTERONE ISOCAPROATE | TESTOSTERONE PHENYLPROPIONATE | TESTOSTERONE PROPIONATE
Last updated on 9 October 2026
Product Info
SUSTANON 250 INJECTION
[SIN04555P]
Product information
Active Ingredient and Strength | TESTOSTERONE DECANOATE - 100 MG/ML |
Dosage Form | INJECTION |
Manufacturer and Country | EVER PHARMA JENA GMBH - GERMANY |
Registration Number | SIN04555P |
Licence Holder | DCH AURIGA SINGAPORE |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | G03BA03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
Testosterone replacement therapy in male with primary and secondary hypogonadal disorders, (either congenital or acquired) when testosterone deficiency has been confirmed by clinical features and biochemical tests, for example:
After castration,
Eunuchoidism,
Hypopituitarsim,
Endocrine impotence,
Male climacteric symptoms such as decreased libido and decreased mental and physical activity,
Certain types of infertility due to disorders of spermatogenesis
In female to male transsexuals:masculinization.
Dosing
4.2 Posology and method of administration
Posology:
In general, the dose should be adjusted according to the response of the individual patient.
Adults (incl. elderly):
Usually, one injection of 1 ml per three weeks is adequate.
Paediatric population:
Safety and efficacy have not been adequately determined in children and adolescents.
Method of administration:
Sustanon should be administered by deep intramuscular injection.
Contraindications
4.3 Contraindications
Known or suspected carcinoma of the prostate or breast (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hypersensitivity to the active substance or to any of the excipients, including arachis oil. Sustanon is therefore contraindicated in patients allergic to peanuts or soya (see section 4.4. – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)